Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Blood (2022) 140 (Supplement 1): 9335–9337.

https://doi.org/10.1182/blood-2022-163180

Published: 2022

Journal Articles

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

Blood (2022) 140 (Supplement 1): 1849–1851.

https://doi.org/10.1182/blood-2022-166329

Published: 2022

Journal Articles

PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma

Pere Barba, Marta Ligero, Cecilia Carpio, Maria Balaguer, Víctor Navarro Garcés, Sabela Bobillo, Francisco Beas, Pau Abrisqueta, Roser Sala, Francesc Bosch, Gloria Iacoboni, Marc Simo, Raquel Perez-Lopez

Blood (2022) 140 (Supplement 1): 3783–3784.

https://doi.org/10.1182/blood-2022-167172

Published: 2022

Journal Articles

Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications

Blood (2022) 140 (Supplement 1): 9266–9268.

https://doi.org/10.1182/blood-2022-168552

Published: 2022

Journal Articles

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Pau Abrisqueta, Raul Cordoba, Lorenzo Falchi, Sven de Vos, Marcel Nijland, Fritz Offner, Jun Wu, Irina Bykhovski, Liwei Wang, Ali Rana, Tycel Phillips

Blood (2022) 140 (Supplement 1): 1068–1069.

https://doi.org/10.1182/blood-2022-158278

Published: 2022

Journal Articles

Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Fernando Martín Moro, Leyre Bento De Miguel, Juan Marquet Palomanes, Antonio Gutierrez, Antonio Diaz-Lopez, Jose M. Sanchez, Jose Antonio Garcia Vela, Antonio Salar, Raul Cordoba, Silvana Novelli, Maria J. Rodriguez-Salazar, Sonia González de Villambrosia, Raquel Del Campo, Hugo Daniel Luzardo Henriquez, Daniel Garcia, Juan-Manuel Sancho, Pau Abrisqueta, Alejandro Martín García-Sancho, Mariana Bastos-Oreiro

Blood (2022) 140 (Supplement 1): 779–781.

https://doi.org/10.1182/blood-2022-170854

Published: 2022

Journal Articles

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 378–380.

https://doi.org/10.1182/blood-2022-169219

Published: 2022

Journal Articles

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Angel Serna, Angela Sanchez, Laia Lopez, Juan-Manuel Sancho, Eva Gonzalez Barca, Alberto Lopez-Garcia, Raul Cordoba, Adolfo Jesús Sáez Marín, Ana Isabel Jiminez Ubieto, Ainara Ferrero, Tomas García, Alba Cabirta, M Moraima Jimenez, Lucia Martin, Marta Julia, Sabela Bobillo, Ana Marin-Niebla, Francesc Bosch, Pau Abrisqueta

Blood (2022) 140 (Supplement 1): 9350–9352.

https://doi.org/10.1182/blood-2022-165996

Published: 2022

Journal Articles

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Blood (2022) 140 (Supplement 1): 9347–9349.

https://doi.org/10.1182/blood-2022-160073

Published: 2022

Journal Articles

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Blood (2022) 140 (Supplement 1): 9342–9344.

https://doi.org/10.1182/blood-2022-163165

Published: 2022

Journal Articles

Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic

Blood (2022) 140 (Supplement 1): 2628–2630.

https://doi.org/10.1182/blood-2022-169321

Published: 2022

Journal Articles

L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

Johannes Duell, Wojciech Jurczak, Anna Marina Liberati, Janusz Halka, Esther Pena Carbó, Pau Abrisqueta Costa, Kami J. Maddocks, Martin Dreyling, Andreas Rosenwald, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles

Blood (2022) 140 (Supplement 1): 6596–6598.

https://doi.org/10.1182/blood-2022-159983

Published: 2022

Journal Articles

Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL-112)

Juan-Manuel Sancho, Pau Abrisqueta, Abhijeet Kumar, Raul Cordoba, Monica Tani, Teng Liu, Erica Rappold, Peter Langmuir, Armando Lopez-Guillermo

Blood (2022) 140 (Supplement 1): 9328–9330.

https://doi.org/10.1182/blood-2022-159703

Published: 2022

Journal Articles

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Blood (2022) 140 (Supplement 1): 1464–1466.

https://doi.org/10.1182/blood-2022-158203

Published: 2022

Journal Articles

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

Catherine S. Diefenbach, Brad S. Kahl, Lalita Banerjee, Andrew K. McMillan, Fiona Miall, Javier Briones, Raul Cordoba, John M. Burke, Jamie Hirata, Sunil Sharma, Lisa Musick, Pau Abrisqueta Costa

Blood (2022) 140 (Supplement 1): 2286–2288.

https://doi.org/10.1182/blood-2022-157720

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Blood (2022) 140 (Supplement 1): 1471–1473.

https://doi.org/10.1182/blood-2022-158232

Published: 2022

Journal Articles

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2021-154729

Published: 2021

Journal Articles

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Blood (2021) 138 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2021-148361

Published: 2021

Journal Articles

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Blood (2021) 138 (Supplement 1): 3850.

https://doi.org/10.1182/blood-2021-147670

Published: 2021

Journal Articles

Early Relapse after First Line Has a Significant Impact on Overall Survival in Patients with Mantle Cell Lymphoma (MCL)

Alba Cabirta, Pau Abrisqueta, Carla Sanchez-Ruiz, Sabela Bobillo, Cecilia Carpio, Gloria Iacoboni, Mercedes Gironella Mesa, Marta Julia, Angel Serna, Carlos Palacio, Josep Castellvi, Francesc Bosch, Ana Marin-Niebla

Blood (2021) 138 (Supplement 1): 1357.

https://doi.org/10.1182/blood-2021-150400

Published: 2021

NARROW

Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma

Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic

L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL-112)

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Early Relapse after First Line Has a Significant Impact on Overall Survival in Patients with Mantle Cell Lymphoma (MCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only